Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045452 | 0.86 | CA12 (0.50) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL13144514 | 0.84 | MAPT (0.70) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL914552 | 0.84 | RAB9A (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL961587 | 0.83 | CA12 (0.52) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL1531795 | 0.83 | RAB9A (0.62) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL424300 | 0.83 | MAPT (0.46) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL163667 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL1438508 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL9454202 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL19208916 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1083 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743081-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4041730-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260109695-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | PI INDUSTRIES LTD. (IN) | 2026-03-17 | — | — | US | disclosed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260053393-A1 | NEAR-IR GLUCOSE SENSORS | PROFUSA INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-0398425-B1 | Antirhinoviral piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA NV (BE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0199324-B1 | NEW 2,5-DIARYL TETRYHYDROFURANS AND ANALOGS THEREOF AS PAF ANTAGONISTS | MERCK & CO. INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5030727-A | Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0398425-A1 | Antirhinoviral piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109695-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX5 | RAB9A 1426/4885MAPT 4515/4885NPC1 3491/4885 |
| US-20260053393-A1 | NEAR-IR GLUCOSE SENSORS | INSR, IRS1, SLC2A4 | RAB9A 3216/4885MAPT 935/4885NPC1 906/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | RAB9A 779/4885MAPT 4504/4885NPC1 1748/4885 |
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX2 | RAB9A 1459/4885MAPT 4676/4885NPC1 3747/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | RAB9A 3362/4885MAPT 4819/4885NPC1 1398/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | RAB9A 2977/4885MAPT 3089/4885NPC1 1460/4885 |
| US-12577239-B2 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | SULT1E1, CBR1, SULT1A1 | RAB9A 1666/4885MAPT 4878/4885NPC1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.